Long-term neuropeptide Y administration in the periphery induces abnormal baroreflex sensitivity and obesity in rats

Cell Physiol Biochem. 2012;29(1-2):111-20. doi: 10.1159/000337592. Epub 2012 Mar 1.

Abstract

Neuropeptide Y (NPY) is an important neuronal element involved in cardiovascular regulation. Since elevated plasma levels of NPY have been observed in numerous pathological situations, this study aimed to determine whether long-term elevated plasma concentrations of NPY could result in aberrant baroreflex sensitivity. Mini-osmotic pump containing NPY (85 μg per 30 days) was subcutaneously implanted between scapulae in male rats for 4 months. The rats treated with NPY showed the following characters compared with control group: (1) attenuated heart rate responding to the increases in mean arterial blood pressure (MABP) induced by phenylephrine, but enhanced heart rate responding to the decreases in MABP induced by sodium nitroprusside; (2) decreased protein levels of substance P (SP) and GluR2, while increased the expression of γ-aminobutyric acid A receptor (GABA(A)R) in brainstem; (3) abdominal obesity indicated by increased body weight and accumulated fat mass in peritoneal cavity; (4) significant increases in total cholesterol, triglycerides, and low density lipoprotein levels in the periphery. These findings indicate that long-term NPY administration in the periphery leads to abnormal baroreflex sensitivity due, at least in part, to the down-regulated expression of SP/GluR2 and elevated expression of GABA(A)R in both protein and RNA levels, which indicate the alternations in glutamate function and GABA action in the nucleus tractus solitarii in NPY-treated rats. Furthermore, long-term NPY administration results in abdominal obesity and dyslipidemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Baroreflex / drug effects*
  • Blood Pressure / drug effects
  • Cholesterol / metabolism
  • Heart Rate / drug effects
  • Lipoproteins, LDL / metabolism
  • Male
  • Neuropeptide Y / pharmacology*
  • Nitroprusside / pharmacology
  • Obesity / etiology*
  • Obesity / metabolism
  • Rats
  • Rats, Wistar
  • Receptors, AMPA / genetics
  • Receptors, AMPA / metabolism
  • Receptors, GABA-A / genetics
  • Receptors, GABA-A / metabolism
  • Substance P / genetics
  • Substance P / metabolism
  • Triglycerides / metabolism
  • Weight Gain / drug effects

Substances

  • Lipoproteins, LDL
  • Neuropeptide Y
  • Receptors, AMPA
  • Receptors, GABA-A
  • Triglycerides
  • Nitroprusside
  • Substance P
  • Cholesterol
  • glutamate receptor ionotropic, AMPA 2